Arsenal Biosciences Raises $325M in Series C
Arsenal Biosciences has successfully raised $325M in a Series C led by Arch Venture Partners, T. Rowe Price Associates.
Company Overview
Arsenal Biosciences is a HealthTech company headquartered in South San Francisco, CA, founded in 2019 with 150+ employees.
Cell therapy company developing programmable T-cell therapies for solid tumors
Fundraising Details
- Amount Raised: $325M
- Round Type: Series C
- Date: 2025-08-22
- Investors: Arch Venture Partners, T. Rowe Price Associates
About Arsenal Biosciences
Cell therapy company developing programmable T-cell therapies for solid tumors The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: South San Francisco, CA
- Founded: 2019
- Team Size: 150+
- Industry: HealthTech
What This Means
This funding round demonstrates strong investor confidence in Arsenal Biosciences's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Arsenal Biosciences's successful fundraising reflects the strong fundamentals and growth potential in this space.
Looking Ahead
With this new capital, Arsenal Biosciences is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
---
This fundraising news was reported on 2025-08-22. For more information about Arsenal Biosciences, visit their headquarters at South San Francisco, CA.
